| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.
|
J Natl Cancer Inst
|
2004
|
14.97
|
|
2
|
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
|
Gastroenterology
|
2009
|
4.50
|
|
3
|
Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.
|
Clin Chem
|
2005
|
3.71
|
|
4
|
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.
|
Cancer Prev Res (Phila)
|
2011
|
3.33
|
|
5
|
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.
|
Cancer Prev Res (Phila)
|
2011
|
3.03
|
|
6
|
A compendium of potential biomarkers of pancreatic cancer.
|
PLoS Med
|
2009
|
3.00
|
|
7
|
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.
|
Clin Chem
|
2007
|
2.38
|
|
8
|
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
2.36
|
|
9
|
The human proteome project: current state and future direction.
|
Mol Cell Proteomics
|
2011
|
2.34
|
|
10
|
Markers for early detection of cancer: statistical guidelines for nested case-control studies.
|
BMC Med Res Methodol
|
2002
|
2.26
|
|
11
|
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.
|
Clin Chem
|
2007
|
2.23
|
|
12
|
Proteomics for cancer biomarker discovery.
|
Clin Chem
|
2002
|
1.57
|
|
13
|
The word "cancer": how language can corrupt thought.
|
BMJ
|
2013
|
1.51
|
|
14
|
Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women.
|
Int J Cancer
|
2005
|
1.51
|
|
15
|
Challenges for biomarkers in cancer detection.
|
Ann N Y Acad Sci
|
2004
|
1.38
|
|
16
|
Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics.
|
Mol Cell Proteomics
|
2006
|
1.24
|
|
17
|
Recent advances in biomarkers for cancer diagnosis and treatment.
|
Drug Discov Today
|
2005
|
1.23
|
|
18
|
Results of the prospective multicenter trial of robotically assisted totally endoscopic coronary artery bypass grafting.
|
Ann Thorac Surg
|
2006
|
1.21
|
|
19
|
Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools.
|
Cancer Res
|
2007
|
1.21
|
|
20
|
Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer.
|
Dis Markers
|
2004
|
1.18
|
|
21
|
Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens.
|
Am J Clin Pathol
|
2008
|
1.15
|
|
22
|
Biomarkers for prostate cancer detection.
|
J Urol
|
2007
|
1.14
|
|
23
|
Mitochondrial DNA as a cancer biomarker.
|
J Mol Diagn
|
2005
|
1.11
|
|
24
|
Early detection of sporadic pancreatic cancer: summative review.
|
Pancreas
|
2015
|
1.10
|
|
25
|
Anti-HER2 IgY antibody-functionalized single-walled carbon nanotubes for detection and selective destruction of breast cancer cells.
|
BMC Cancer
|
2009
|
1.07
|
|
26
|
The Early Detection Research Network's Specimen reference sets: paving the way for rapid evaluation of potential biomarkers.
|
Clin Chem
|
2012
|
1.05
|
|
27
|
Proteomic analysis of cancer-cell mitochondria.
|
Nat Rev Cancer
|
2003
|
1.05
|
|
28
|
Epigenetics in cancer: implications for early detection and prevention.
|
Lancet Oncol
|
2002
|
1.05
|
|
29
|
New cancer biomarkers deriving from NCI early detection research.
|
Recent Results Cancer Res
|
2003
|
1.02
|
|
30
|
Performance of mitochondrial DNA mutations detecting early stage cancer.
|
BMC Cancer
|
2008
|
1.02
|
|
31
|
The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop.
|
Cancer Biomark
|
2008
|
1.01
|
|
32
|
Evaluation of anti-ulcerogenic and ulcer-healing properties of Ocimum sanctum Linn.
|
J Ethnopharmacol
|
2004
|
1.01
|
|
33
|
Multiple strand displacement amplification of mitochondrial DNA from clinical samples.
|
BMC Med Genet
|
2008
|
1.00
|
|
34
|
The promise of biomarkers in cancer screening and detection.
|
Trends Mol Med
|
2002
|
0.99
|
|
35
|
The human proteome project: Current state and future direction.
|
Mol Cell Proteomics
|
2011
|
0.96
|
|
36
|
Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests.
|
J Proteomics
|
2012
|
0.96
|
|
37
|
The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology.
|
Urol Oncol
|
2004
|
0.95
|
|
38
|
A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum.
|
J Proteome Res
|
2013
|
0.94
|
|
39
|
Systematic, evidence-based discovery of biomarkers at the NCI.
|
Clin Exp Metastasis
|
2012
|
0.92
|
|
40
|
New paradigms in translational science research in cancer biomarkers.
|
Transl Res
|
2012
|
0.92
|
|
41
|
Epigenetics and cancer.
|
Crit Rev Clin Lab Sci
|
2004
|
0.91
|
|
42
|
Long-gradient separations coupled with selected reaction monitoring for highly sensitive, large scale targeted protein quantification in a single analysis.
|
Anal Chem
|
2013
|
0.90
|
|
43
|
Joint National Cancer Institute-Food and Drug Administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
0.90
|
|
44
|
Biomarkers in molecular medicine: cancer detection and diagnosis.
|
Biotechniques
|
2005
|
0.90
|
|
45
|
Workshop on imaging science development for cancer prevention and preemption.
|
Cancer Biomark
|
2007
|
0.87
|
|
46
|
Immobilization strategies for single-chain antibody microarrays.
|
Proteomics
|
2008
|
0.86
|
|
47
|
Quantitation of HER2 and telomerase biomarkers in solid tumors with IgY antibodies and nanocrystal detection.
|
Int J Cancer
|
2008
|
0.86
|
|
48
|
Standards for plasma and serum proteomics in early cancer detection: a needs assessment report from the national institute of standards and technology--National Cancer Institute Standards, Methods, Assays, Reagents and Technologies Workshop, August 18-19, 2005.
|
Clin Chem
|
2006
|
0.86
|
|
49
|
Facile whole mitochondrial genome resequencing from nipple aspirate fluid using MitoChip v2.0.
|
BMC Cancer
|
2008
|
0.86
|
|
50
|
Mitochondria as a target for early detection and diagnosis of cancer.
|
Crit Rev Clin Lab Sci
|
2005
|
0.86
|
|
51
|
The biology of incipient, pre-invasive or intraepithelial neoplasia.
|
Cancer Biomark
|
2010
|
0.86
|
|
52
|
Advances in Biomedical Imaging, Bioengineering, and Related Technologies for the Development of Biomarkers of Pancreatic Disease: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases and National Institute of Biomedical Imaging and Bioengineering Workshop.
|
Pancreas
|
2015
|
0.83
|
|
53
|
Cancer biomarkers: an emerging means of detecting, diagnosing and treating cancer.
|
Cancer Biomark
|
2005
|
0.81
|
|
54
|
ERG monoclonal antibody in the diagnosis and biological stratification of prostate cancer: delineation of minimal epitope, critical residues for binding, and molecular basis of specificity.
|
Monoclon Antib Immunodiagn Immunother
|
2014
|
0.81
|
|
55
|
Biomarkers in oncology research and treatment: early detection research network: a collaborative approach.
|
Biomark Med
|
2008
|
0.80
|
|
56
|
Chemical constituents and antifilarial activity of Lantana camara against human lymphatic filariid Brugia malayi and rodent filariid Acanthocheilonema viteae maintained in rodent hosts.
|
Parasitol Res
|
2006
|
0.80
|
|
57
|
Translational pathology of neoplasia.
|
Cancer Biomark
|
2010
|
0.79
|
|
58
|
High-throughput analysis of telomerase by capillary electrophoresis.
|
Electrophoresis
|
2003
|
0.79
|
|
59
|
Molecular diagnostics: a new frontier in cancer prevention.
|
Expert Rev Mol Diagn
|
2004
|
0.79
|
|
60
|
The promise of biomarkers in colorectal cancer detection.
|
Dis Markers
|
2004
|
0.79
|
|
61
|
Nanotechnology in early detection of cancer.
|
Lab Invest
|
2002
|
0.78
|
|
62
|
Move over proteomics, here comes glycomics.
|
J Proteome Res
|
2008
|
0.78
|
|
63
|
Cancer biomarkers: an emerging means of detecting, diagnosing and treating cancer.
|
Dis Markers
|
2005
|
0.77
|
|
64
|
Strategic approach to validating methylated genes as biomarkers for breast cancer.
|
Cancer Prev Res (Phila)
|
2010
|
0.77
|
|
65
|
Analytical validation of telomerase activity for cancer early detection: TRAP/PCR-CE and hTERT mRNA quantification assay for high-throughput screening of tumor cells.
|
J Mol Diagn
|
2004
|
0.77
|
|
66
|
Wuchereria bancrofti: effect of single and multiple larval inoculations on infection dynamics and development of clinical manifestations in non-human primate Presbytis entellus.
|
Exp Parasitol
|
2006
|
0.77
|
|
67
|
Developing recombinant antibodies for biomarker detection.
|
Cancer Biomark
|
2010
|
0.77
|
|
68
|
Biomarkers for cancer diagnosis: implications for nutritional research.
|
J Nutr
|
2004
|
0.77
|
|
69
|
Preparation and characterization of candidate reference materials for telomerase assays.
|
Clin Chem
|
2005
|
0.76
|
|
70
|
Data standards for proteomics: mitochondrial two-dimensional polyacrylamide gel electrophoresis data as a model system.
|
Mitochondrion
|
2004
|
0.76
|
|
71
|
A simple packed bed device for antibody labelled rare cell capture from whole blood.
|
Lab Chip
|
2012
|
0.76
|
|
72
|
Nutritional links to plausible mechanisms underlying pancreatic cancer: a conference report.
|
Pancreas
|
2003
|
0.76
|
|
73
|
Murine infection model for Mycobacterium fortuitum.
|
Microbes Infect
|
2005
|
0.76
|
|
74
|
Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report.
|
Pancreas
|
2016
|
0.75
|
|
75
|
Early Detection of Pancreatic Cancer-a Defined Future Using Lessons From Other Cancers: A White Paper.
|
Pancreas
|
2016
|
0.75
|
|
76
|
Standards for immunohistochemical imaging: a protein reference device for biomarker quantitation.
|
J Histochem Cytochem
|
2010
|
0.75
|
|
77
|
Cancer genetics in the post genomic era.
|
Curr Mol Med
|
2007
|
0.75
|
|
78
|
Detecting role of apoptosis in mediating cyclophosphamide induced teratogenesis in vitro.
|
Toxicol Mech Methods
|
2005
|
0.75
|
|
79
|
Cancer biomarkers. Preface.
|
Cancer Biomark
|
2005
|
0.75
|
|
80
|
Noncoding RNAs in molecular characterization of cancer preneoplasia.
|
Cancer Biomark
|
2010
|
0.75
|
|
81
|
Proteomics in diagnostics.
|
Dis Markers
|
2004
|
0.75
|
|
82
|
A vanishing lesion.
|
JACC Cardiovasc Interv
|
2010
|
0.75
|
|
83
|
Nanotechnology: Emerging Developments and Early Detection of Cancer. A two-day workshop sponsored by the National Cancer Institute and the National Institute of Standards and Technology, August 30-31 2001, on the National Institute of Standards and Technology Campus, Gaithersburg, MD, USA.
|
Dis Markers
|
2002
|
0.75
|
|
84
|
Standards in molecular diagnostics for the discovery and validation of clinically useful cancer biomarkers.
|
Expert Rev Mol Diagn
|
2013
|
0.75
|
|
85
|
Translational pathology of early cancer.
|
Cancer Biomark
|
2010
|
0.75
|
|
86
|
Biomarkers in public health.
|
Cancer Biomark
|
2012
|
0.75
|